



# Are ObGyns offering the range of treatment options for early pregnancy failure?

**NO** The findings of this survey of 976 ObGyns, midwives, and family medicine practitioners suggest that modern approaches to early pregnancy failure (EPF) are much underutilized.

Although misoprostol administration and office evacuation of uterine contents have each been demonstrated to be safe, effective, and economical, 52.7% of ObGyn respondents reported that they had not used misoprostol for EPF during the 6 months preceding the survey, and only 16.2% had performed office uterine evacuation. Rather, most respondents continue to rely on expectant management or perform uterine evacuation under general anesthesia in the operating room.

*Dalton VK, Harris LH, Gold KJ, et al. Provider knowledge, attitudes, and treatment preferences for early pregnancy failure. Am J Obstet Gynecol. 2010;202(6):531.e1-e8.*

## ► EXPERT COMMENTARY

**Andrew M. Kaunitz, MD**, Professor and Associate Chairman, Department of Obstetrics and Gynecology, University of Florida College of Medicine—Jacksonville, Jacksonville, Fla. Dr. Kaunitz serves on the OBG MANAGEMENT Board of Editors.

One in every four women experiences EPF. Although office uterine evacuation and misoprostol administration are less invasive and less expensive alternatives to traditional OR evacuation, it is not clear how extensively clinicians employ these options in the United States.<sup>1,2</sup>

In 2008, Dalton and colleagues surveyed ObGyns, certified nurse midwives (CNMs), and family physicians (FPs) in the United States who had evaluated or treated, or both, a woman for EPF in the preceding 6 months. They achieved response rates of 51.0%, 70.9%, and 53.5%, respectively. Evaluable respondents had a mean age of 49 to 50 years and

included 309 ObGyns (46.9% of whom were female), 368 CNMs (97.8% female), and 299 FPs (43.6% female).

Overall, approximately one third of respondents believe that office evacuation is riskier than OR evacuation. In addition, 65.7% of ObGyns believe that most patients prefer OR evacuation, compared with 46.2% and 43.1% of CNMs and FPs, respectively ( $P < .001$ ). Among ObGyns, an adjusted analysis estimated the likelihood of providing office evacuation to be five times higher among those who have undergone training in induced abortion ( $P < .05$ ). As for misoprostol for EPF, about two thirds of respondents overall believe that it is safe.

Dalton and associates posit that providers “perceive that their personal treatment preferences are different than their patients’ Whether this discordance results in

## WHAT THIS EVIDENCE MEANS FOR PRACTICE

Certainly, women have diverse preferences for how EPF is managed, but many do find office evacuation and misoprostol to be acceptable methods. Accordingly, we should offer all options to them. As the investigators in this study suggest, we may need to focus on correcting inaccurate beliefs about these modalities among providers to increase their willingness to offer them.

The findings of this survey also underscore the fact that training programs that do not teach induced abortion—or that allow trainees to opt out of such training—can compromise the care provided to women who have EPF.

» ANDREW M. KAUNITZ, MD

## FAST TRACK

A survey revealed that 52.7% of ObGyn respondents had not used misoprostol for early pregnancy failure during the 6 months preceding the survey, and only 16.2% had performed office uterine evacuation

women undergoing operating room uterine evacuation more often than is necessary or preferred could not be assessed by this study.” However, the authors also assert that, “given that providers affect treatment choice greatly, it is plausible that provider treatment preferences are an important influence on current treatment patterns.”

#### References

1. Zhang J, Gilles JM, Barnhart K, et al. A comparison of medical management with misoprostol and surgical management for early pregnancy failure. *N Engl J Med.* 2005;353(8):761-769.
2. Harris LH, Dalton VK, Johnson TR. Surgical management of early pregnancy failure: history, politics, and safe, cost-effective care. *Am J Obstet Gynecol.* 2007;196(5):445.e1-e5.

Look what's  
coming  
in October

**OBG**  
MANAGEMENT

**NEW!**

A digital edition of **OBG MANAGEMENT**  
at [obgmanagement.com](http://obgmanagement.com)

Update on **pelvic floor surgery**  
by Dr. Cindy Amundsen  
and Dr. Amie Kawasaki

Answers from imaging:  
**Skilled US imaging of the adnexal mass**  
**Part 2: Nonneoplastic ovarian masses**  
by Dr. Ilan Timor and Dr. Steven Goldstein

Dr. Andrew M. Kaunitz responds to questions  
about the care of women who take an  
**aromatase inhibitor**  
to prevent the recurrence or advance  
of breast cancer

## PRODUCT UPDATE

### NONINVASIVE, DISPOSABLE COLD THERAPY FOR HEMORRHOID RELIEF

**CryoSTAT** is a new, disposable, noninvasive cryotherapy product on the market for hemorrhoid relief. Hemorrhoids can develop from pregnancy and childbirth. Direct application of **CryoSTAT** provides prompt relief of swelling and inflammation, and calms itching, burning, and pain. The cold therapy pack is surrounded by a soft, comfortable cloth, is not messy to use, and is available over the counter. ■

FOR MORE INFORMATION: [www.cryostatrelief.com](http://www.cryostatrelief.com)

### COOK MEDICAL OFFERS ASSISTED REPRODUCTIVE TECHNOLOGY INFORMATION

New educational resources, faster access to assisted reproductive technology (ART) product information, and improved user functionality are features of the recently updated **CookARTLab.com** from Cook Medical. The Web site includes an interactive tour of an ART lab where visitors can view real-world demonstrations of various techniques, participate in a discussion forum, and access a news center and links to current research. ■

FOR MORE INFORMATION: [www.CookARTLab.com](http://www.CookARTLab.com)

### NEW SOLUTIONS FOR PPH AND VAGINAL REPAIR FROM GLENVEIGH MEDICAL

Glenveigh Medical recently announced that two new products have received FDA clearance: the **ebb Complete Tamponade System** and the **jetty Vaginal Repair Balloon**.

- The **ebb Complete Tamponade System** is indicated for temporary treatment of postpartum hemorrhage (PPH), the leading cause of maternal mortality worldwide. The **ebb**, a rapid-response balloon device, provides complete tamponade, with capacity for total conformation to the uterine cavity. Through direct rapid inflation via an IV bag spike, dual balloons allow quick, secure treatment of both uterine and vaginal bleeding.

- It is estimated that 700,000 episiotomies are performed annually in the US, and other injuries can be caused by instruments during vaginal deliveries. The **jetty Vaginal Repair Balloon** is indicated for use in episiotomy and vaginal laceration repair to temporarily prevent postpartum fluids from discharging from the vagina. The **jetty** replaces the use of packing sponges, thus reducing the chance for infection. ■

FOR MORE INFORMATION: [www.glenveigh.com](http://www.glenveigh.com)

### FREE CME WEBINAR: POSTPARTUM DEPRESSION IN THE CULTURAL CONTEXT

The New Jersey Department of Health and Senior Services is offering a **free Webinar** for health care providers who treat women of childbearing age and/or pregnant patients. Dr. James Boehnlein (Oregon Health & Science University) and an expert panel present culturally appropriate ways to assess, treat, and refer patients with postpartum depression. Participants can earn one Continuing Medical Education (CME) credit, and do not need to be NJ residents. ■

TO VIEW THE WEBINAR:

<http://mededppd.org/NJDHSS/index.html>